Cytek Biosciences, Inc. (CTKB) Guidance & Earnings Results
On 2026-08-05 Cytek Biosciences, Inc. raised guidance: "FY2026 revenue guidance raised to $207-212M (midpoint up…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CTKBCytek Biosciences, Inc.Follow CTKB — free
—
Price chart with a free account
- Market cap
- 726.6M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 5 Aug 26 | Raised | FY2026 revenue guidance raised to $207-212M (midpoint up $1M) · full year |
| 7 May 26 | Reaffirmed | FY2026 revenue $205-212M (2-5% growth) · full year |
| 5 Nov 25 | Reaffirmed | Reaffirms 2025 revenue guidance of $196M-$205M · full year |
| 6 Aug 25 | Mixed | FY2025 revenue narrowed to $196-205M from prior range (not explicitly stated but implied narrowing); growth of -2% to +2% over FY2024 · full year |
Cytek Biosciences, Inc. — questions
- What guidance did Cytek Biosciences, Inc. give?
- On 2026-08-05: "FY2026 revenue guidance raised to $207-212M (midpoint up $1M)"
- When does Cytek Biosciences, Inc. report earnings?
- Cytek Biosciences, Inc.'s next earnings report is expected on 2026-11-11.
Every figure on this page comes from Cytek Biosciences, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.